GABRIELA NAVAR: Open Payments
NPI 1144709023 · EL PASO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$702 in 36 payments from 11 companies in 2025. Trend: 2023 $697 · 2024 $503 · 2025 $702
Food & beverage: $702
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 9 | $162 |
| Amgen Inc. | 9 | $139 |
| GlaxoSmithKline, LLC. | 4 | $79 |
| Corcept Therapeutics | 3 | $77 |
| Novartis Pharmaceuticals Corporation | 2 | $65 |
| PFIZER INC. | 3 | $50 |
| Lilly USA, LLC | 2 | $41 |
| GENZYME CORPORATION | 1 | $28 |
| AstraZeneca Pharmaceuticals LP | 1 | $22 |
| Exact Sciences Corporation | 1 | $20 |
Products named: OTEZLA, TRELEGY ELLIPTA, Korlym, LEQVIO, Ozempic, Wegovy, NURTEC ODT, MOUNJARO.
Industry payments across TX — which companies pay providers there.
